Financial Performance Forecast - The company expects a net profit attributable to shareholders for 2024 to be between 600 million and 650 million CNY, an increase of 259.93 million to 309.93 million CNY compared to the previous year, representing a year-on-year increase of 76.44% to 91.14%[3] - The expected net profit attributable to shareholders after deducting non-recurring gains and losses for 2024 is projected to be between 410 million and 460 million CNY, an increase of 112.84 million to 162.84 million CNY compared to the previous year, reflecting a year-on-year increase of 37.97% to 54.80%[3] - The total profit for the previous year was 306.14 million CNY, with a net profit attributable to shareholders of 340.07 million CNY and a net profit after deducting non-recurring gains and losses of 297.16 million CNY[6] - The performance forecast is based on preliminary estimates and has not been audited by certified public accountants[5] - There are no major uncertainties affecting the accuracy of this performance forecast[8] - The data provided is preliminary and the final financial figures will be disclosed in the official 2024 annual report[9] Revenue Growth - The company achieved steady growth in domestic and international revenue, with significant sales increases in key markets such as Indonesia, India, and Algeria[7] - The company has maintained its product selection status in the new round of centralized procurement, contributing to sustained domestic revenue growth[7] Impact of Non-Recurring Gains - Non-recurring gains and losses significantly impacted net profit, primarily due to increased fair value gains on trading financial assets influenced by market fluctuations[7] Announcement Details - The announcement was made by the board of directors on January 21, 2025[11]
甘李药业(603087) - 2024 Q4 - 年度业绩预告